Our Call to Policymakers
Demand 1
Data Infrastructure
The Government should commission SteroidSafe to deliver a large-scale, national prevalence study of anabolic steroids and all image and performance enhancing drug use across gyms, needle exchanges and online surveys, including research into long-term physical and mental health outcomes, and build the data infrastructure to measure ongoing consequences.
Demand 2
Clinical Response & Safeguarding
The NHS should develop clinical pathways specifically for steroid-related conditions, underpinned by clinical guidelines from the National Institute for Health and Care Excellence, ensuring these are consistently applied across the health sector with required inclusion in NHS clinical training including reducing the stigma from clinicians.
DWP: The Department for Work and Pensions should recognise anabolic steroid misuse as a health condition in its own right, and train Personal Independence Payment and Universal Credit assessors to identify steroid use as a contributing factor in physical and mental health conditions.
Safeguarding: The Department for Education should update ‘Keeping Children Safe in Education’ to include anabolic steroid use as a recognised safeguarding concern, ensuring school Designated Safeguarding Leads are equipped to identify signs of use in under-18s.
Demand 3
Regulated Pathway
Possession being legal while supply and production remain criminalised has created a void in legislation. Users source compounds from the black market via social media with no quality control and no guarantee of purity or dosage.
The Home Office should commission the Advisory Council on the Misuse of Drugs to review the scheduling of anabolic steroids. The MHRA should determine which compounds may be dispensed. The Government should then introduce a regulated pathway through licensed pharmacies, substantially self-funding through margins on sales cross-subsidising consultations and blood work while remaining price-competitive with the black market.
Required safeguards
Users currently on unapproved compounds would be offered lower-risk alternatives. Needle exchanges should be required to refer steroid users into the regulated pathway.